EU pharmacies resist wholesaling changes; Teva cutting 200 at Irvine plant;

> EU pharmacy leaders oppose the Medicines and Healthcare Products Regulatory Agency's plan to review drug wholesaling practices with an eye toward eliminating complexity. Article

> Generics-maker Teva Pharmaceuticals is cutting 200 production and support-staff jobs at its Irvine, CA, plant, most by the first week in February. Story

> Shire has completed construction of a manufacturing plant in the Boston suburb of Lexington, in which it plans to make Replagal and Vpriv. Article

> AstraZeneca is continuing its serialization push: ten manufacturing sites and 30 production lines now produce drugs having item-level serial numbers on their packaging. Article

> Grand Bahama eyes the drug and chemical industries in its ambition to become a transportation and logistics hub for maritime and air cargo operations. Item

> The UK's Fairfield Group has launched a scanner that reads 2D data matrix barcodes in addition to traditional barcodes and Pharmacodes. Fairfield release

> Catalent Pharma Solutions is enhancing its sourcing program for the supply of comparator drugs used in clinical trials. Catalent release

> Actavis Group has expanded its geothermally powered, zero-carbon-footprint tablet manufacturing and packaging operation in Iceland. News

> Both the FDA and ASHP maintain drug-shortage lists; the FDA's includes nearly 60 medically necessary products while the more comprehensive ASHP list includes more than 140 drugs. Report

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.